AAPL342.92-0.55 (-0.16%) ▼|ABBV284.42-1.00 (-0.35%) ▼|ABT104.32-0.57 (-0.54%) ▼|ACN235.20+5.52 (+2.40%) ▲|ADBE246.56+1.36 (+0.55%) ▲|AMAT417.31+8.02 (+1.96%) ▲|AMD539.43+10.68 (+2.02%) ▲|AMGN428.11-4.39 (-1.01%) ▼|AMT182.00-3.28 (-1.77%) ▼|AMZN262.08+12.08 (+4.83%) ▲|AVGO335.37+6.62 (+2.01%) ▲|AXP315.88+2.29 (+0.73%) ▲|BA191.26+1.05 (+0.55%) ▲|BAC50.45-0.78 (-1.52%) ▼|BKNG161.95-1.50 (-0.92%) ▼|BLK1,125.72-8.66 (-0.76%) ▼|BMY59.10-0.65 (-1.09%) ▼|BNY143.18-0.12 (-0.08%) ▼|BRK-B532.48+0.46 (+0.09%) ▲|C122.37-1.89 (-1.52%) ▼|CAT727.56-3.20 (-0.44%) ▼|CL93.49-0.62 (-0.66%) ▼|CMCSA22.03+0.13 (+0.59%) ▲|COF199.96-1.78 (-0.88%) ▼|COP145.42-1.09 (-0.74%) ▼|COST995.54+6.43 (+0.65%) ▲|CRM242.31+1.61 (+0.67%) ▲|CSCO107.09-0.30 (-0.28%) ▼|CVS91.62-0.74 (-0.80%) ▼|CVX224.99-0.01 (0.00%) ▼|DE629.09-12.77 (-1.99%) ▼|DHR224.75-4.30 (-1.88%) ▼|DIS109.89-0.70 (-0.63%) ▼|DUK119.75-1.72 (-1.42%) ▼|EMR160.78-0.69 (-0.43%) ▼|FDX292.70-0.85 (-0.29%) ▼|GD342.86-1.38 (-0.40%) ▼|GE312.88-0.95 (-0.30%) ▼|GEV911.55-9.65 (-1.05%) ▼|GILD154.70-1.49 (-0.95%) ▼|GM82.61-1.35 (-1.61%) ▼|GOOG340.22+3.31 (+0.98%) ▲|GOOGL344.34+3.75 (+1.10%) ▲|GS875.52-5.74 (-0.65%) ▼|HD310.46+0.83 (+0.27%) ▲|HON210.47-0.95 (-0.45%) ▼|IBM236.90+4.76 (+2.05%) ▲|INTC92.51+2.66 (+2.96%) ▲|INTU325.96+0.81 (+0.25%) ▲|ISRG433.05+6.35 (+1.49%) ▲|JNJ254.24-1.33 (-0.52%) ▼|JPM334.90-4.83 (-1.42%) ▼|KO93.87-0.03 (-0.03%) ▼|LIN504.07+5.64 (+1.13%) ▲|LLY1,251.71-5.32 (-0.42%) ▼|LMT553.09+1.00 (+0.18%) ▲|LOW196.35-1.03 (-0.52%) ▼|LRCX274.09+10.15 (+3.84%) ▲|MA615.72-1.70 (-0.28%) ▼|MCD243.09+0.12 (+0.05%) ▲|MDLZ63.56-0.35 (-0.55%) ▼|MDT93.08-1.67 (-1.76%) ▼|META702.62-6.71 (-0.95%) ▼|MMM163.13-1.63 (-0.99%) ▼|MO74.79-0.32 (-0.43%) ▼|MRK144.48-1.47 (-1.01%) ▼|MS179.14-1.43 (-0.79%) ▼|MSFT534.16+5.11 (+0.97%) ▲|MU905.25+26.41 (+3.00%) ▲|NEE78.35-1.46 (-1.82%) ▼|NFLX69.52-1.01 (-1.43%) ▼|NKE37.11-0.03 (-0.07%) ▼|NOW144.64+2.67 (+1.88%) ▲|NVDA217.40+3.27 (+1.53%) ▲|ORCL130.04+1.81 (+1.41%) ▲|PEP133.22+1.73 (+1.32%) ▲|PFE29.47-0.12 (-0.39%) ▼|PG158.19-1.16 (-0.73%) ▼|PLTR194.27+8.24 (+4.43%) ▲|PM202.88-2.33 (-1.13%) ▼|QCOM173.54+1.43 (+0.83%) ▲|RTX193.17-0.75 (-0.39%) ▼|SBUX98.10+0.58 (+0.59%) ▲|SCHW89.99-1.97 (-2.14%) ▼|SO89.81-1.37 (-1.50%) ▼|SPG202.59-2.85 (-1.39%) ▼|T23.34-0.11 (-0.45%) ▼|TMO679.81-10.19 (-1.48%) ▼|TMUS157.88-1.22 (-0.77%) ▼|TSLA368.00+13.28 (+3.74%) ▲|TXN276.41-0.08 (-0.03%) ▼|UBER70.33-0.03 (-0.04%) ▼|UNH405.18+3.75 (+0.93%) ▲|UNP287.87-1.17 (-0.40%) ▼|UPS97.15-0.33 (-0.34%) ▼|USB58.17-0.57 (-0.96%) ▼|V403.61+1.00 (+0.25%) ▲|VZ44.38-0.41 (-0.92%) ▼|WFC82.48-1.39 (-1.66%) ▼|WMT119.22+0.41 (+0.34%) ▲|XOM178.67-0.31 (-0.17%) ▼|AAPL342.92-0.55 (-0.16%) ▼|ABBV284.42-1.00 (-0.35%) ▼|ABT104.32-0.57 (-0.54%) ▼|ACN235.20+5.52 (+2.40%) ▲|ADBE246.56+1.36 (+0.55%) ▲|AMAT417.31+8.02 (+1.96%) ▲|AMD539.43+10.68 (+2.02%) ▲|AMGN428.11-4.39 (-1.01%) ▼|AMT182.00-3.28 (-1.77%) ▼|AMZN262.08+12.08 (+4.83%) ▲|AVGO335.37+6.62 (+2.01%) ▲|AXP315.88+2.29 (+0.73%) ▲|BA191.26+1.05 (+0.55%) ▲|BAC50.45-0.78 (-1.52%) ▼|BKNG161.95-1.50 (-0.92%) ▼|BLK1,125.72-8.66 (-0.76%) ▼|BMY59.10-0.65 (-1.09%) ▼|BNY143.18-0.12 (-0.08%) ▼|BRK-B532.48+0.46 (+0.09%) ▲|C122.37-1.89 (-1.52%) ▼|CAT727.56-3.20 (-0.44%) ▼|CL93.49-0.62 (-0.66%) ▼|CMCSA22.03+0.13 (+0.59%) ▲|COF199.96-1.78 (-0.88%) ▼|COP145.42-1.09 (-0.74%) ▼|COST995.54+6.43 (+0.65%) ▲|CRM242.31+1.61 (+0.67%) ▲|CSCO107.09-0.30 (-0.28%) ▼|CVS91.62-0.74 (-0.80%) ▼|CVX224.99-0.01 (0.00%) ▼|DE629.09-12.77 (-1.99%) ▼|DHR224.75-4.30 (-1.88%) ▼|DIS109.89-0.70 (-0.63%) ▼|DUK119.75-1.72 (-1.42%) ▼|EMR160.78-0.69 (-0.43%) ▼|FDX292.70-0.85 (-0.29%) ▼|GD342.86-1.38 (-0.40%) ▼|GE312.88-0.95 (-0.30%) ▼|GEV911.55-9.65 (-1.05%) ▼|GILD154.70-1.49 (-0.95%) ▼|GM82.61-1.35 (-1.61%) ▼|GOOG340.22+3.31 (+0.98%) ▲|GOOGL344.34+3.75 (+1.10%) ▲|GS875.52-5.74 (-0.65%) ▼|HD310.46+0.83 (+0.27%) ▲|HON210.47-0.95 (-0.45%) ▼|IBM236.90+4.76 (+2.05%) ▲|INTC92.51+2.66 (+2.96%) ▲|INTU325.96+0.81 (+0.25%) ▲|ISRG433.05+6.35 (+1.49%) ▲|JNJ254.24-1.33 (-0.52%) ▼|JPM334.90-4.83 (-1.42%) ▼|KO93.87-0.03 (-0.03%) ▼|LIN504.07+5.64 (+1.13%) ▲|LLY1,251.71-5.32 (-0.42%) ▼|LMT553.09+1.00 (+0.18%) ▲|LOW196.35-1.03 (-0.52%) ▼|LRCX274.09+10.15 (+3.84%) ▲|MA615.72-1.70 (-0.28%) ▼|MCD243.09+0.12 (+0.05%) ▲|MDLZ63.56-0.35 (-0.55%) ▼|MDT93.08-1.67 (-1.76%) ▼|META702.62-6.71 (-0.95%) ▼|MMM163.13-1.63 (-0.99%) ▼|MO74.79-0.32 (-0.43%) ▼|MRK144.48-1.47 (-1.01%) ▼|MS179.14-1.43 (-0.79%) ▼|MSFT534.16+5.11 (+0.97%) ▲|MU905.25+26.41 (+3.00%) ▲|NEE78.35-1.46 (-1.82%) ▼|NFLX69.52-1.01 (-1.43%) ▼|NKE37.11-0.03 (-0.07%) ▼|NOW144.64+2.67 (+1.88%) ▲|NVDA217.40+3.27 (+1.53%) ▲|ORCL130.04+1.81 (+1.41%) ▲|PEP133.22+1.73 (+1.32%) ▲|PFE29.47-0.12 (-0.39%) ▼|PG158.19-1.16 (-0.73%) ▼|PLTR194.27+8.24 (+4.43%) ▲|PM202.88-2.33 (-1.13%) ▼|QCOM173.54+1.43 (+0.83%) ▲|RTX193.17-0.75 (-0.39%) ▼|SBUX98.10+0.58 (+0.59%) ▲|SCHW89.99-1.97 (-2.14%) ▼|SO89.81-1.37 (-1.50%) ▼|SPG202.59-2.85 (-1.39%) ▼|T23.34-0.11 (-0.45%) ▼|TMO679.81-10.19 (-1.48%) ▼|TMUS157.88-1.22 (-0.77%) ▼|TSLA368.00+13.28 (+3.74%) ▲|TXN276.41-0.08 (-0.03%) ▼|UBER70.33-0.03 (-0.04%) ▼|UNH405.18+3.75 (+0.93%) ▲|UNP287.87-1.17 (-0.40%) ▼|UPS97.15-0.33 (-0.34%) ▼|USB58.17-0.57 (-0.96%) ▼|V403.61+1.00 (+0.25%) ▲|VZ44.38-0.41 (-0.92%) ▼|WFC82.48-1.39 (-1.66%) ▼|WMT119.22+0.41 (+0.34%) ▲|XOM178.67-0.31 (-0.17%) ▼|
18 C
New York
Monday, October 19, 2026

Tag: Amgen

newssourceFORcompanycontentinformation1releasesmarket

Leading Drug Delivery Conference PODD Announces its 15th Annual Agenda

The Conference Forum announces the 15th annual PODD Drug Delivery Conference's 2025 agenda and featured sessions. NEW YORK, July 16, 2025 /PRNewswire/ -- Today, PODD: Partnership...

Draig Therapeutics Appoints Experienced Biotech Leader Douglas E. Williams, Ph.D. as Chair of its Board of Directors

Cardiff, United Kingdom – 15 July 2025 – Draig Therapeutics (“Draig”), a clinical-stage company aiming to transform the treatment of neuropsychiatric diseases, today announces the appointment of Douglas E. Williams, Ph.D. as independent Chair of its Board of Directors. He takes over from Ruth McKernan, who retains her role on the Board as a Director and Interim Chief Executive Officer (CEO).

Cancer Cachexia Market Anticipates Impressive Growth Trajectory at a CAGR of 8.9% During the Forecast Period (2025-2034) | DelveInsight

The cancer cachexia market is expected to witness an expansion across the 7MM, driven by the introduction of innovative therapies, ponsegromab (PF-06946860), S-pindolol benzoate...

Cancer Cachexia Market Anticipates Impressive Growth Trajectory at a CAGR of 8.9% During the Forecast Period (2025-2034) | DelveInsight

The cancer cachexia market is expected to witness an expansion across the 7MM, driven by the introduction of innovative therapies, ponsegromab (PF-06946860), S-pindolol benzoate...

BCC Research Releases 2024 Protein Synthesis Research Review

"Driving Innovation and Sustainability: The Vital Role of Protein Synthesis in Modern Biotechnology and Its Impact on Chronic Disease Treatment, Technological Advances, and Market...

BCC Research Releases 2024 Protein Synthesis Research Review

"Driving Innovation and Sustainability: The Vital Role of Protein Synthesis in Modern Biotechnology and Its Impact on Chronic Disease Treatment, Technological Advances, and Market...

Celltrion USA announces U.S. launch of denosumab biosimilars, STOBOCLO® and OSENVELT® (denosumab-bmwo)

STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) are approved by FDA for all indications of PROLIA® (denosumab) and XGEVA® (denosumab) respectively,STOBOCLO and OSENVELT, among the first...

GPRC5D-directed Therapies Market is Anticipated to Gain Momentum During the Forecast Period (2025-2034) Owing to Unmet Need in Multiple Myeloma | DelveInsight

The GPRC5D-directed therapies market is witnessing robust growth, driven by the high unmet need in relapsed/refractory multiple myeloma. Innovative modalities like CAR-T cells, bispecific...

GPRC5D-directed Therapies Market is Anticipated to Gain Momentum During the Forecast Period (2025-2034) Owing to Unmet Need in Multiple Myeloma | DelveInsight

The GPRC5D-directed therapies market is witnessing robust growth, driven by the high unmet need in relapsed/refractory multiple myeloma. Innovative modalities like CAR-T cells, bispecific...

Oxford BioTherapeutics Announces Third Oncology Drug Candidate from Boehringer Ingelheim Collaboration Selected to Advance into IND-Enabling Studies

Drug candidate is one of several oncology assets approaching or in clinical development, discovered through Oxford BioTherapeutics’ proprietary OGAP®-Verify discovery platform

GPCR-Targeting Therapies Market Poised for Strong Growth During the Forecast Period (2025-2034) Across 7MM Due to the Rising Cancer Diagnoses and Drug Pipeline Expansion...

The GPCR-targeting therapies market is expected to grow significantly in the coming years. This is due to the increasing number of patients who are...

GPCR-Targeting Therapies Market Poised for Strong Growth During the Forecast Period (2025-2034) Across 7MM Due to the Rising Cancer Diagnoses and Drug Pipeline Expansion...

The GPCR-targeting therapies market is expected to grow significantly in the coming years. This is due to the increasing number of patients who are...

Cancer Therapeutics Market Forecast to Reach $168 Billion by 2029, Highlighting Recurrent and Metastatic Innovations

"Metastatic Cancer: A Significant Therapeutic Challenge as Pharmaceutical Companies Leverage Digital Platforms and Data to Enhance Engagement with Patients, Providers, and Regulators in the...

Anti-CCR8 Antibodies Market to Witness Remarkable Growth Trajectory During the Forecast Period (2025-2040) Across 7MM | DelveInsight

The anti-CCR8 antibodies market holds potential in addressing unmet needs across inflammatory and cancerous diseases. The anti-CCR8 inhibitor market is expected to witness substantial...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsAmgen

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers